Company Update (NASDAQ:AMGN): Amgen files for U.S. approval of biosimilar to Humira

[Reuters] – Amgen Inc on Wednesday said it filed with U.S. health regulators seeking approval to sell its first biosimilar drug, which would be a less expensive alternative to AbbVie’s Humira, the world’s . . . → Read More: Company Update (NASDAQ:AMGN): Amgen files for U.S. approval of biosimilar to Humira Similar Articles: Market Update (NASDAQ:AMGN): Novartis biosimilar copycat takes aim at Amgen’s drug Enbrel Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s leukemia drug gets conditional European approval Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215